Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

mRNA vaccines and monoclonal antibodies protect against new NYC-B.1.526 variant

A new fast-spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called B.1.526 recently emerged in New York City and caused concerns for its potential to resist the immune system.

28 Mar 2021

Scientists share insights on operationalizing monoclonal antibody therapy for COVID-19

As evidence mounts supporting the use of monoclonal antibody treatment to reduce hospitalizations and deaths from COVID-19, UPMC and University of Pittsburgh School of Medicine physician-scientists are sharing the health system's experience administering the life-saving medication.

26 Mar 2021

Scientists estimate the amount of peanut protein that will elicit an allergic reaction

An estimated 6 million Americans may suffer from peanut allergies. Tiny amounts of peanut protein can lead to hives, itching, tingling in the mouth, shortness of breath or nausea within minutes.

26 Mar 2021

Longitudinal study of SARS-CoV-2 antibodies following vaccination

A longitudinal study of IgG antibody levels in vaccinated healthcare workers was recently uploaded to the preprint server medRxiv*, suggesting that IgG levels could be a reliable indicator of successful vaccination.

26 Mar 2021

One dose of Pfizer vaccine generates strong immune response against COVID-19

A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.

26 Mar 2021

Antibody used for COVID-19 therapy does not inhibit SARS-Cov-2 variants

Cell culture studies show that mutated viruses are less susceptible to inhibition by antibodies from recovered or vaccinated individuals.

26 Mar 2021

Study shows substantial benefit of combination therapy for advanced Marburg infections

A new study conducted at the Galveston National Laboratory at the The University of Texas Medical Branch at Galveston has shown substantial benefit to combining monoclonal antibodies and the antiviral remdesivir against advanced Marburg virus.

25 Mar 2021

Study observes correlation between COVID-19 mortality and autoantibodies in corticosteroid treated patients

Corticosteroid anti-inflammatory drugs have been applied to COVID-19 patients over the course of the pandemic, though the results are mixed. In a recent study, the outcomes for such patients are collated, demonstrating a striking correlation between the development of autoantibodies and mortality.

25 Mar 2021

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

A team of scientists from the USA and Canada recently characterized the cross-neutralizing potency of anti-SARS-CoV-2 antibodies isolated from COVID-19 patients. The findings reveal that some of the isolated antibodies targeting the spike RBD and the S2 subunit are capable of cross-neutralizing other members of the human beta-coronavirus family.

25 Mar 2021

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

The scientific consensus is that safe and highly effective vaccines are required to end the ongoing pandemic of coronavirus disease 2019 COVID-19, caused by SARS-CoV-2. A new study describes a new vaccine that presents two viral antigens to the human immune system, in order to elicit a more efficacious response.

25 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

COVID vaccines have only 17% detectable antibodies against SARS-CoV-2 virus

When clinical trials were conducted to determine the immunogenicity -- the ability to elicit an immune response -- for the first two vaccines marshaled against SARS-CoV-2the virus that causes COVID-19, one group was not among those included: people who have received solid organ transplants and others (such as those with autoimmune disorders) who are immunocompromised.

25 Mar 2021

Researchers discover a novel marker of adult human neural stem cells

The mammalian center for learning and memory, hippocampus, has a remarkable capacity to generate new neurons throughout life. Newborn neurons are produced by neural stem cells (NSCs) and they are crucial for forming neural circuits required for learning and memory, and mood control.

24 Mar 2021

Reduced mRNA COVID-19 vaccine response in nursing home residents

A recent study has examined the response of nursing home residents who were naïve to SARS-CoV-2 infection following vaccination by the mRNA BNT162b2 model from Pfizer-BioNTech.

24 Mar 2021

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Researchers at the Division of Infection and Immunity, University College London, UK, have provided key insights into the characteristics of the B.1.1.7 (or UK) variant of SARS-CoV-2.

24 Mar 2021

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

A new study adds to the sum of knowledge about SARS-CoV-2, with respect to its natural and biologically significant mutations, using computational modeling of the virus-receptor interactions. Understanding how viral mutations affect the virus-host interactions is crucial for shaping proper strategies to control the virus.

24 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

A new preprint study led by Shawn S-C. Li from Western University in Ontario, Canada, provides evidence of epitope-specific antibody responses and designed a test to measure this in relation to disease severity and outcome after infection.

24 Mar 2021

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.

24 Mar 2021

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

The CVnCoV mRNA vaccine showed neutralizing antibody levels and completely protected mice infected with the B.1.351 variant. No viral genomes were seen in oral swabs, lungs, or brain.

23 Mar 2021

Antibody News and Research

Further Reading

mRNA vaccines and monoclonal antibodies protect against new NYC-B.1.526 variant

Scientists share insights on operationalizing monoclonal antibody therapy for COVID-19

Scientists estimate the amount of peanut protein that will elicit an allergic reaction

Longitudinal study of SARS-CoV-2 antibodies following vaccination

One dose of Pfizer vaccine generates strong immune response against COVID-19

Antibody used for COVID-19 therapy does not inhibit SARS-Cov-2 variants

Study shows substantial benefit of combination therapy for advanced Marburg infections

Study observes correlation between COVID-19 mortality and autoantibodies in corticosteroid treated patients

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

COVID vaccines have only 17% detectable antibodies against SARS-CoV-2 virus

Researchers discover a novel marker of adult human neural stem cells

Reduced mRNA COVID-19 vaccine response in nursing home residents

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo